Madorra

Executive Summary

Madorra is a Palo Alto-based medical device company developing a nonhormonal, noninvasive treatment for vaginal dryness, a common yet undertreated condition affecting post-menopausal women and breast cancer survivors. Unlike existing pharmaceutical options that rely on hormones, Madorra's approach targets the underlying physiology without systemic side effects, offering a new choice for patients who cannot or prefer not to use hormonal therapies. The company aims to disrupt the women's health market, which has historically been underserved despite a large patient population seeking safer, effective alternatives. Founded in 2014, Madorra has remained private without disclosed funding, indicating a lean operation focused on product development and regulatory strategy. The market opportunity is significant, with millions of women experiencing vaginal atrophy and dryness, particularly among the growing aging population and the increasing number of breast cancer survivors. Madorra's solution has the potential to capture a substantial share of the nonhormonal segment, which is currently limited to lubricants and moisturizers that provide only temporary relief. While the company has not publicly disclosed its stage or financing, the lack of disclosures suggests it may still be in early-stage development or preclinical/clinical testing. Key upcoming milestones could include securing seed or Series A funding to advance its device through clinical trials and regulatory clearance, which would be critical for validating its technology and bringing a much-needed option to market. The company's success hinges on demonstrating safety and efficacy in well-designed studies and navigating the FDA's regulatory pathway for novel medical devices.

Upcoming Catalysts (preview)

• TBDSeries A Funding Round50% success
• TBDInitiation of Pivotal Clinical Trial40% success
• TBDFDA Breakthrough Device Designation30% success